scholarly journals Melanoma to papillary thyroid carcinoma: A case of tumor-to-tumor metastasis to the head and neck and a re-evaluation of diagnostic criteria

2020 ◽  
Vol 22 ◽  
pp. 200445
Author(s):  
Dennis E. Curry ◽  
Matthew H. Rigby ◽  
Martin Bullock
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Head And Neck ◽  
Diagnostic Criteria ◽  
Tumor Metastasis ◽  
Papillary Thyroid ◽  
Tumor To Tumor Metastasis

Tumor-to-Tumor Metastasis to Follicular Variant of Papillary Carcinoma of Thyroid

1999 ◽  
Vol 123 (8) ◽  
pp. 703-706 ◽  
Author(s):  
Zubair W. Baloch ◽  
Virginia A. LiVolsi
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Gland ◽  
Thyroid Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Metastasis ◽  
Small Cell ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Tumor To Tumor Metastasis ◽  
Tumor Metastases

Abstract Objective.—To describe and document tumor-to-tumor metastases in the thyroid gland. Methods and Results.—In this series we describe 3 cases of tumor-to-tumor metastasis in which the recipient tumor was a follicular variant of papillary thyroid carcinoma. The donor tumors and sites were small cell carcinoma of the lung, neuroendocrine carcinoma probably of pancreatic origin with initial presentation as liver metastasis, and clear cell carcinoma of the kidney with metastasis to liver and pancreas. The donor tumor cells infiltrated the substance of the follicular variant of papillary thyroid carcinoma, the nontumorous thyroid parenchyma, and the lymphovascular spaces. Small cell carcinoma and neuroendocrine carcinoma showed positive reactivity for neuroendocrine markers and were negative for thyroglobulin and calcitonin. The follicular variant of papillary thyroid carcinoma showed positivity with thyroglobulin and cytokeratin 19. Conclusions.—Although tumor-to-tumor metastases in thyroid gland are exceedingly rare, one should be aware of this phenomenon as the metastatic lesion may simulate a thyroid primary. History of a previous tumor and immunohistochemical stains can be helpful in distinguishing between primary and metastatic thyroid neoplasms.

Tumor-to-tumor metastasis: Lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma

2011 ◽  
Vol 61 (7) ◽  
pp. 435-441 ◽  
Author(s):  
Kazuki Hashimoto ◽  
Hidetaka Yamamoto ◽  
Takafumi Nakano ◽  
Minako Oyama ◽  
Hideki Shiratsuchi ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Lung Adenocarcinoma ◽  
Tumor Metastasis ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Tumor To Tumor Metastasis

scholarly journals Cutaneous metastases on the head and neck from a papillary thyroid carcinoma, follicular variant

2016 ◽  
Vol 107 (1) ◽  
pp. 83-85
Author(s):  
A. Márquez García ◽  
L. Ferrándiz Pulido ◽  
J.J. Ríos-Martín ◽  
F.M. Camacho Martínez
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Head And Neck ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Cutaneous Metastases

scholarly journals Effect of Implementing the New Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in King Abdulaziz University Hospital

2016 ◽  
Vol 23 (3) ◽  
pp. 31-37
Author(s):  
Fatimah A. Alturkistani ◽  
Murad A. Alturkustani
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Diagnostic Criteria ◽  
University Hospital ◽  
Thyroid Neoplasm ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
King Abdulaziz University ◽  
Nuclear Features

Pathological diagnosis of follicular variant of papillary thyroid carcinoma has high inter and intra-observer variability among expert pathologists, aff ecting prognosis and management of the disease. A recent study applying strict diagnostic criteria and long-term follow up confi rmed the indolent behavior of a subtype of these tumors. They recommended a nomenclature change to noninvasive follicular thyroid neoplasm with papillary-like nuclear features, refl ecting the low risk of adverse outcomes. We searched the pathology archives of King Abdulaziz University Hospital from 2002-2016 for all cases diagnosed with “follicular variant of papillary thyroid carcinoma”. Clinical data, and imaging fi ndings were retrospectively reviewed. Available pathologyslides were reviewed using the proposed inclusion and exclusion diagnostic criteria. We confi rmed the diagnostic reproducibility of the suggested criteria. Ten out of 37 cases met the diagnostic criteria. Eightadditional patients could have had their diagnosis modifi ed if sufficient tissue samples were available. Follow up data confi rmed the indolent behavior in these cases with no recurrence or adverse outcome. We concluded that application of the new diagnostic criteria for this subtype is reasonable and has major ramifi cations for the diagnosis and management as this will spare unnecessary thyroidectomies, radioactive iodine therapy, and their complications.

scholarly journals Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT

2015 ◽  
Vol 22 (3) ◽  
pp. 419-429 ◽  
Author(s):  
Matthias S Dettmer ◽  
Anja Schmitt ◽  
Hans Steinert ◽  
David Capper ◽  
Holger Moch ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Diagnostic Criteria ◽  
Adverse Outcome ◽  
Braf V600e ◽  
Molecular Diagnostic ◽  
Papillary Thyroid ◽  
Tumor Relapse ◽  
Tall Cell ◽  
Promoter Mutations

The tall cell (TC) variant of papillary thyroid carcinoma (PTC) has an unfavorable prognosis. The diagnostic criteria remain inconsistent, and the role of a minor TC component is unclear. Molecular diagnostic markers are not available; however, there are two potential candidates:BRAF V600Eand telomerase reverse transcriptase (TERT) promoter mutations. Using a novel approach, we enriched a collective with PTCs that harbored an adverse outcome, which overcame the limited statistical power of most studies. This enabled us to review 125 PTC patients, 57 of which had an adverse outcome. The proportion of TCs that constituted a poor prognosis was assessed. All of the tumors underwent sequencing forTERTpromoter andBRAFV600Emutational status and were stained with an antibody to detect theBRAFV600Emutation. A 10% cutoff for TCs was significantly associated with advanced tumor stage and lymph node metastasis. Multivariate analysis showed that TCs above 10% were the only significant factor for overall, tumor-specific, and relapse-free survival. Seven percent of the cases had aTERTpromoter mutation, whereas 61% demonstrated aBRAFmutation. The presence of TC was significantly associated withTERTpromoter andBRAFmutations.TERTpredicted highly significant tumor relapse (P<0.001). PTCs comprised of at least 10% TCs are associated with an adverse clinical outcome and should be reported accordingly.BRAFdid not influence patient outcome. Nevertheless, a positive status should encourage the search for TCs.TERTpromoter mutations are a strong predictor of tumor relapse, but their role as a surrogate marker for TCs is limited.

Palliative tracheal stenting in invasive papillary thyroid carcinoma

2001 ◽  
Vol 115 (11) ◽  
pp. 935-937 ◽  
Author(s):  
C. Hopkins ◽  
M. Stearns ◽  
A. F. Watkinson
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Pulmonary Function ◽  
Head And Neck ◽  
Current Literature ◽  
Tracheal Stenosis ◽  
Physiological Data ◽  
Papillary Thyroid

Malignant tracheal stenosis presents a considerable challenge to the head and neck surgeon. The use of intraluminal stents has been previously described, but current literature notes a paucity of supportive physiological data. We describe the use of a self-expanding metallic Wallstent in the palliation of a case of papillary thyroid carcinoma. This is accompanied by significant improvement in quantitative pulmonary function.

Sign in / Sign up

Export Citation Format

Share Document